Medicare Enrolled

Dr. Umesh Patel, M.D.

Rheumatology · Fishkill, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
200 WESTAGE BUSINESS CTR DR, Fishkill, NY 12524
8458978717
In practice since 2008 (17 years)
NPI: 1811146236 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Patel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Patel

Dr. Umesh Patel is a rheumatology specialist in Fishkill, NY, with 17 years of NPI registration. Based on federal Medicare data, Dr. Patel performed 79,503 Medicare services across 350 unique beneficiaries.

Between the years covered by Open Payments, Dr. Patel received a total of $14,206 from 41 pharmaceutical and/or device companies across 811 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Patel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 6% volume in NY $14,206 industry payments

Medicare Practice Summary

Medicare Utilization ↗
79,503
Medicare services
Top 6% in NY for rheumatology
350
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,677 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
78,400 $4 $15
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
579 $98 $207
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
401 $11 $50
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
51 $132 $324
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
43 $63 $149
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
29 $76 $238
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$14,206
Total received (2018-2024)
Avg $2,029/year across 7 years
Top 23% in NY for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
811
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,206 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,956
2023
$2,302
2022
$1,880
2021
$1,477
2020
$1,002
2019
$2,427
2018
$2,163

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$778
Amgen Inc.
$425
Janssen Biotech, Inc.
$384
UCB, Inc.
$202
Boehringer Ingelheim Pharmaceuticals, Inc.
$196
E.R. Squibb & Sons, L.L.C.
$185
Lilly USA, LLC
$179
Novartis Pharmaceuticals Corporation
$159
GlaxoSmithKline, LLC.
$80
AstraZeneca Pharmaceuticals LP
$68
Octapharma USA, Inc.
$53
Organon Llc
$53
ANI Pharmaceuticals, Inc.
$45
Aurinia Pharma U.S., Inc.
$40
PFIZER INC.
$39
Mallinckrodt Hospital Products Inc.
$23
Sandoz Inc.
$23
Kiniksa Pharmaceuticals International, plc
$23
Top 3 companies account for 53.7% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,933
Amgen Inc.
$1,830
PFIZER INC.
$1,638
Novartis Pharmaceuticals Corporation
$1,500
ABBVIE INC.
$1,487
UCB, Inc.
$1,432
Lilly USA, LLC
$708
E.R. Squibb & Sons, L.L.C.
$583
AbbVie, Inc.
$437
GlaxoSmithKline, LLC.
$361
Boehringer Ingelheim Pharmaceuticals, Inc.
$317
Celgene Corporation
$262
AbbVie Inc.
$257
Regeneron Healthcare Solutions, Inc.
$155
Organon LLC
$148
AstraZeneca Pharmaceuticals LP
$135
Aurinia Pharma U.S., Inc.
$123
Octapharma USA, Inc.
$91
Mallinckrodt Hospital Products Inc.
$83
Horizon Therapeutics plc
$72
Antares Pharma, Inc.
$63
Fresenius Kabi USA, LLC
$53
Organon Llc
$53
Horizon Pharma plc
$51
PROCEPT BioRobotics Corporation
$49
ANI Pharmaceuticals, Inc.
$45
Exeltis, USA Inc.
$32
FIDIA PHARMA USA INC.
$31
Alexion Pharmaceuticals, Inc.
$29
Genentech USA, Inc.
$27
Endo Pharmaceuticals Inc.
$24
Kiniksa Pharmaceuticals, Ltd.
$24
Sandoz Inc.
$23
Kiniksa Pharmaceuticals International, plc
$23
GENZYME CORPORATION
$22
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$21
UROVANT SCIENCES INC
$21
Radius Health, Inc.
$17
Coloplast Corp
$17
Ultragenyx Pharmaceutical Inc.
$16
Cook Incorporated
$11
Top 3 companies account for 38.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AQUABEAM ROBOTIC SYSTEM · AVEED · Actemra · Arcalyst · BENLYSTA · Bimzelx · COOK MEDICAL CELECT PLATINUM · COSENTYX · CYLTEZO · Cimzia · EVENITY · Enbrel · GEMTESA · HADLIMA · HUMIRA · HYRIMOZ · Humira · Hymovis · ILARIS · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · LUPKYNIS · NOCDURNA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OLUMIANT · ORENCIA · OTREXUP · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · RAYOS · REMICADE · RENFLEXIS · REYVOW · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · SOLIRIS · SPEVIGO · STELARA · SpeediCath · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · VIMOVO · XELJANZ · XIFAXAN
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Fishkill?
Compare rheumatologists in the Fishkill area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
29
Per 100K population
9.8
County median income
$97,273
Nearest hospital
MONTEFIORE ST LUKE'S CORNWALL
8.9 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Patel is a mixed practice specialist, with above-average Medicare volume (top 6% in NY), with low-engagement industry engagement, with 17 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Patel experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Patel performed 78,400 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patel receive payments from pharmaceutical companies?
Yes. Dr. Patel received a total of $14,206 from 41 companies across 811 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patel's costs compare to other rheumatologists in Fishkill?
Dr. Patel's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →